Advances in immunotherapy of pancreatic ductal adenocarcinoma

VernacularTitle: 胰腺导管腺癌的免疫治疗进展
Author: Jiaqi YANG ¹ ; Tao WEI ; Yiwen CHEN ; Xueli BAI ; Tingbo LIANG
Author Information

1. Department of Hepatopancreatobiliary Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Key Laboratory of Pancreatic Disease of Zhejiang Province, Hangzhou 310009, China
Publication Type:Review
Keywords: Pancreatic neoplasms; Tumor microenvironment; Immune microenvironment; Immunotherapy
From: Chinese Journal of Surgery 2017;55(5):396-400
CountryChina
Language:Chinese
Abstract: The morbidity of pancreatic ductal adenocarcinoma (PDAC) has been increasing over years, while the treatment efficacy and prognosis of PDAC remain far from satisfying. The newly-ermerged tumor immunotherapy has not only made lots of breakthroughs in various malignancies, but also brought an opportunity to the treatment of pancreatic cancer.PDAC immunotherapies, mainly including vaccine therapy, adoptive T cell thanfer therapy, checkpoint blockade therapy, have achieved a certain effect, however, the clinical outcomes have not been satisfactory. Therefore, the combination of immunotherapies based on different theoretical views is important and is likely to be the trend in the future. Carcinoma associated fibroblast (CAF) is the most common cell in pancreatic cancer stromal component. It will be helpful to develop more potential therapeutic targets by further exploring CAF and the mechanism of fibrosis mediated immunosuppression.